Shore ND, George DJ, Khan N, Constantinovici N, Chen G, Ghadessi M, et al. Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study. Prostate Cancer Prostatic Dis. 2026. https://doi.org/10.1038/s41391-026-01099-3
Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. Prostate Cancer Prostatic Dis. 2025;28:960–7. https://doi.org/10.1038/s41391-025-00969-6.
Google Scholar
Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, et al. Trial design and objectives for patients with prostate cancer: recommendations from the prostate cancer working group 4. J Clin Oncol. 2026;44:1249–65. https://doi.org/10.1200/JCO-25-02834.
Google Scholar
Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, et al. Early favorable prostate-specific antigen response prediction in metastatic hormone-sensitive prostate cancer. Nat Commun. 2025;17:667. https://doi.org/10.1038/s41467-025-67298-z.
Google Scholar
Bushi G, Ullah A, Khan U, Sayyed H, Shabil M. Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials. Int J Clin Oncol. 2025;30:2223–35. https://doi.org/10.1007/s10147-025-02869-0.
Google Scholar
